Research Article| Volume 123, ISSUE 1, P44-49, January 01, 2019

Comparison of In-Hospital Bleeding and Cardiovascular Events with High-Dose Bolus Tirofiban and Shortened Infusion to Short-Duration Eptifibatide as Adjunctive Therapy for Percutaneous Coronary Intervention

Published:September 26, 2018DOI:
      Potent platelet inhibition is one of the most important medical interventions to prevent ischemic complications during and after percutaneous coronary intervention (PCI). Practice has evolved with the introduction of potent oral P2Y12 inhibitors that provide quick, effective platelet inhibition, and the need for routine glycoprotein IIb/IIIa inhibitors (GPIs) has decreased. Additionally, a shorter duration of GPI infusion has been shown to be safe with adequate oral antiplatelet loading, but clinical outcome data are limited to eptifibatide. This single-center, retrospective cohort study analyzed in-hospital outcomes for patients who received adjunctive GPI therapy for PCI before and after an institution-wide switch to high-dose bolus tirofiban with shortened infusion from short-duration eptifibatide. The primary end point was a composite in-hospital outcome of major and minor bleeding and cardiovascular events (death, myocardial infarction, coronary artery bypass grafting, ischemic stroke, and target vessel revascularization). Secondary end points included bleeding and cardiovascular event types. A total of 357 and 446 patients received eptifibatide and tirofiban, respectively, from February 1, 2014 through September 30, 2017. Thirty five eptifibatide and 46 tirofiban patients experienced an in-hospital composite event (9.8% vs 10.3%, p = 0.81). There was no difference found between in-hospital bleeding (6.4% vs 5.4%, p = 0.52) or cardiovascular events (5.6% vs 6.5%, p = 0.60) with the use of eptifibatide or tirofiban, respectively. Multivariable analysis showed that patients with transradial access or an indication of unstable angina were less likely to experience an in-hospital composite event (OR 0.30 and 0.19, respectively, p <0.001 for both). In conclusion, the use of high-dose bolus tirofiban with shortened infusion versus short-duration eptifibatide was not associated with an increase of in-hospital bleeding or cardiovascular events.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Amsterdam EA
        • Wenger NK
        • Brindis RG
        • Casey Jr DE
        • Ganiats TG
        • Holmes Jr DR
        • Jaffe AS
        • Jneid H
        • Kelly RF
        • Kontos MC
        • Levine GN
        • Liebson PR
        • Mukherjee D
        • Peterson ED
        • Sabatine MS
        • Smalling RW
        • Zieman SJ
        2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes.
        J Am Coll Cardiol. 2014; 64: e139-e228
        • O'Gara PT
        • Kushner FG
        • Ascheim DD
        • Casey Jr DE
        • Chung MK
        • de Lemos JA
        • Ettinger SM
        • Fang JC
        • Fesmire FM
        • Franklin BA
        • Granger CB
        • Krumholz HM
        • Linderbaum JA
        • Morrow DA
        • Newby LK
        • Ornato JP
        • Ou N
        • Radford MJ
        • Tamis-Holland JE
        • Tommaso CL
        • Tracy CM
        • Woo YJ
        • Zhao DX
        2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction.
        J Am Coll Cardiol. 2013; 61: e78-e140
        • Kassaian SE
        • Fathi Y
        • Lotfi-Tokaldany M
        • Salarifar M
        • Alidoosti M
        • Haji-Zeinali A
        • Aghajani H
        • Amirzadegan A
        • Nozari Y
        • Mortazavi SH
        • Jalali A
        • Saroukhani S
        Comparison of 1-year major adverse cardiac events in patients undergoing primary percutaneous coronary intervention receiving intracoronary bolus only versus intracoronary bolus plus infusion of glycoprotein IIb/IIIa inhibitors.
        Crit Pathw Cardiol. 2016; 15: 89-94
        • Zhu TQ
        • Zhang Q
        • Qiu JP
        • Jin HG
        • Lu L
        • Shen J
        • Zhao LP
        • Zhang RY
        • Hu J
        • Yang ZK
        • Shen WF
        Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The ICT-AMI study.
        Int J Cardiol. 2013; 165: 437-443
        • Ernst N
        • Suryapranata H
        • Miedema K
        • Slingerland RJ
        • Ottervanger JP
        • Hoorntje J
        • Gosselink A
        • Dambrink J
        • de Boer M
        • Zijlstra F
        • van't Hof A
        Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
        J Am Coll Cardiol. 2004; 44: 1187-1193
        • Marmur JD
        • Poludasu S
        • Agarwal A
        • Manjappa N
        • Cavusoglu E
        High-dose tirofiban administered as bolus-only during percutaneous coronary intervention.
        J Invasive Cardiol. 2008; 20: 53-58
        • Integrilin (eptifibatide)
        Prescribing Information.
        Merck & Co., Inc., Whitehouse Station, NJ2014
        • Aggrastat (tirofiban hydrochloride)
        Prescribing Information.
        Medicure Pharma, Inc., Somerset, NJ2016
        • The IMPACT-II investigators
        Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II.
        Lancet. 1997; 349: 1422-1428
        • The PURSUIT trial investigators
        Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
        N Engl J Med. 1998; 339: 436-443
        • O'Shea JC
        • Hafley GE
        • Greenberg S
        • Hasselblad V
        • Lorenz TJ
        • Kitt MM
        • Strony J
        • Tcheng JE
        Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial.
        JAMA. 2001; 285: 2468-2473
        • The PRISM study investigators
        A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
        N Engl J Med. 1998; 338: 1498-1505
        • The PRISM-PLUS study investigators
        Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
        N Engl J Med. 1998; 338: 1488-1497
        • The RESTORE investigators
        Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.
        Circulation. 1997; 96: 1445-1453
        • Valgimigli M
        • Percoco G
        • Barbieri D
        • Ferrari F
        • Guardigli G
        • Parrinello G
        • Soukhomovskaia O
        • Ferrari R
        The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE trial.
        J Am Coll Cardiol. 2004; 44: 14-19
        • Moliterno DJ.
        A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the Tirofiban Evaluation of Novel Dosing versus Abciximab with Clopidogrel and Inhibition of Thrombin (TENACITY) study trial.
        Catheter Cardiovasc Interv. 2011; 77: 1001-1009
        • Valgimigli M
        • Tebaldi M
        • Gianluca C
        • Gambetti S
        • Bristot L
        • Monti M
        • Parrinello G
        • Ferrari R
        Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
        JACC Cardiovasc Interv. 2012; 5: 268-277
        • Nei SD
        • Armon JJ
        • Dierkhising RA
        • Bell MR
        • Mathew V
        • Barsness GW
        • Ou NN
        Effect of a shortened-duration eptifibatide infusion (75 mg) as adjunctive therapy for percutaneous coronary intervention on inhospital cardiovascular outcomes and bleeding.
        Am J Cardiol. 2015; 115: 707-710
        • Tantry US
        • Bonello L
        • Aradi D
        • Price MJ
        • Jeong YH
        • Angiolillo DJ
        • Stone GW
        • Curzen N
        • Geisler T
        • Ten Berg J
        • Kirtane A
        • Siller-Matula J
        • Mahla E
        • Becker RC
        • Bhatt DL
        • Waksman R
        • Rao SV
        • Alexopoulos D
        • Marcucci R
        • Reny JL
        • Trenk D
        • Sibbing D
        • Gurbel PA
        Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.
        J Am Coll Cardiol. 2013; 62: 2261-2273
        • Schiariti M
        • Saladini A
        • Cuturello D
        • Missiroli B
        • Puddu PE
        Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention.
        J Cardiovasc Med. 2011; 12: 29-36
        • Holmes LE
        • Gupta R
        • Rajendran S
        • Luu J
        • French JK
        • Juergens CP
        A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
        Cardiovasc Ther. 2016; 34: 330-336
        • Valgimigli M
        • Campo G
        • Percoco G
        • Bolognese L
        • Vassanelli C
        • Colangelo S
        • de Cesare N
        • Rodriguez AE
        • Ferrario M
        • Moreno R
        • Piva T
        • Sheiban I
        • Pasquetto G
        • Prati F
        • Nazzaro MS
        • Parrinello G
        • Ferrari R
        Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
        JAMA. 2008; 299: 1788-1799
        • Van't Hof AW
        • ten Berg J
        • Heestermans T
        • Thorsten D
        • Funck RC
        • van Werkum W
        • Dambrink JE
        • Suryapranata H
        • van Houwelingen G
        • Ottervanger JP
        • Stella P
        • Giannitsis E
        • Hamm C
        Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial.
        Lancet. 2008; 372: 537-546
        • Valgimigli M
        • Saia F
        • Guastaroba P
        • Menozzi A
        • Magnavacchi P
        • Santarelli A
        • Passerini F
        • Sangiorgio P
        • Manari A
        • Tarantino F
        • Margheri M
        • Benassi A
        • Sangiorgi MG
        • Tondi S
        • Marzocchi A
        Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngioLastiche dell'Emilia-Romagna) multicenter registry.
        JACC Cardiovasc Interv. 2012; 5: 23-35
        • Mehta SK
        • Frutkin AD
        • Lindsey JB
        • House JA
        • Spertus JA
        • Rao SV
        • Ou FS
        • Roe MT
        • Peterson ED
        • Marso SP
        Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry.
        Circ Cardiovasc Interv. 2009; 2: 222-229
        • Marian MJ
        • Alli O
        • Al Solaiman F
        • Brott BC
        • Sasse M
        • Leesar T
        • Prabhu SD
        • Leesar M
        Ticagrelor and eptifibatide bolus versus ticagrelor and eptifibatide bolus with 2-hour infusion in high-risk acute coronary syndromes patients undergoing early percutaneous coronary intervention.
        J Am Heart Assoc. 2017; 6e005562